Stay updated on Pembrolizumab Plus MK-4830 in Ovarian Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Plus MK-4830 in Ovarian Cancer Clinical Trial page.

Latest updates to the Pembrolizumab Plus MK-4830 in Ovarian Cancer Clinical Trial page
- Check7 days agoChange DetectedAdded Revision: v3.5.2 and removed Revision: v3.5.0.SummaryDifference0.1%

- Check14 days agoNo Change Detected
- Check21 days agoNo Change Detected
- Check36 days agoChange DetectedRevision v3.5.0 was added to the record history and Revision v3.4.3 was removed.SummaryDifference0.1%

- Check43 days agoChange DetectedRevision history updated: added v3.4.3 and removed v3.4.2.SummaryDifference0.1%

- Check71 days agoChange DetectedAdded Revision: v3.4.2 to the history; deletions remove a government-funding notice and the older Revision: v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check78 days agoChange DetectedAdded a government funding lapse notice and a revision note (v3.4.1); removed the previous revision note (v3.4.0). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check86 days agoChange DetectedUI updates in the history page include a Show glossary option and color-coded change highlights (green for additions, red for deletions) with a Revision: v3.4.0 banner. Additionally, the No FEAR Act data entry and the older Revision: v3.3.4 entry were removed.SummaryDifference0.6%

Stay in the know with updates to Pembrolizumab Plus MK-4830 in Ovarian Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Plus MK-4830 in Ovarian Cancer Clinical Trial page.